BioM Biotech Cluster Development GmbH
BioM Biotech Cluster Development GmbH is a publicly funded not-for-profit organization supporting the Bavarian biotech sector. BioM is located in Martinsried, the heart of Munich’s biotech sector. Since 1996, the clustermanagement agency helps to bring the Munich Biotech Cluster m4 further to the international forefront and makes it visible on the global stage. BioM also manages the Bavarian Biotech Cluster, a network of innovative biotech locations including Munich, Regensburg, Erlangen-Nuremberg, Wurzburg, and Straubing. Furthermore, BioM was and currently is involved in several EU projects in the area of cluster development and biotechnology.
For biotechnology companies and start-ups in Bavaria, BioM serves as the central advisory point and helps to find the right partners in its extensive network. BioM offers consulting for grant applications, company foundation, and business development. BioM organizes a wide range of seminars and training as well as networking events for biotech entrepreneurs and their employees. By cooperation with global partners, BioM supports Bavarian biotechnology companies to develop international contacts and to build business in foreign markets. The service agency is active in public relations as well as location marketing and represents the Bavarian biotech industry on national and international trade fairs.
BioM is also the first entry point for global players in biotech and pharma seeking collaborations and business partners in Bavaria. Exclusive partnering events provide an excellent entry point to the region and showcase the biotech cluster’s high potential. With the annual Bavarian Biotech Report, the agency offers condensed information on the sector’s economic data and provides a complete collection of company profiles. It can be downloaded from the homepage www.bio-m.org, which also offers daily news, an events calendar, a job market and much more.
It is your health – and Munich Science provides your “personalized health care”!
The European Metropolitan Region of Munich is home to the most important biotechnology scene in Germany with some 350 life science companies, more than 35,000 employees, several incubators for innovative start-ups (with more than 25.000 sqm state-of-the-art lab-space) and a concentration of large global Biotech and Pharma companies.
In science, 2 „elite universities“ – Ludwig-Maximilians-Universität and Technische Universität München -, 2 university clinics and 60 other hospitals as well as universities of applied sciences focusing on production technologies in biotechnology form the academic basis for innovation.
World renowned science institutions are located in this area: like the 3 Max Planck Institutes of Biochemistry, Neurobiology and Psychiatry. They have very different profiles but a very common characteristic: they are home for world leading scientist like Mathias Mann (proteomics), Axel Ullrich (oncology), Hartmut Wekerle (neuroimmunology), Franz Hartl (structure biology). And there is the Helmholtz Zentrum München – German Research Center for Environmental Health, with leading expertise in genomewide research, the European Mouse Mutant clinic, leading research in Immunology… to name a few.
Additionally Munich is the only place in Germany where all of the new German Centres for Health Research are located, focusing on Infectious Deseases, Cardiovascular, Diabetics, Neurodegenerative disorders, Lung diseases, Oncology.
In the last few years international biotech players recognized the greater Munich area as “place to be”: AMGEN acquired Micromet for more than 1 bn US$ in 2012 and runs their largest research facility outside the US in Munich to fully integrate the bispecific antibody technology of former Micromet. Celgene, Gilead, Vertex, Biogen, Myriad … have their german site located in Munich. Exosome Diagnostics opened its R&D facility in Martinsried-Munich to develop its first Dx-Kit for non-invasive Exosome analysis together with Qiagen. Baxter acquired Martinsried Suppremol for 200 m€ in 2015 and will keep the site to further develop generalized immunotherpeutics.
Roche Diagnostics, located in Penzberg near Munich, employs about 5.500 in one of Europe´s largest production plant for biologics and diagnostics.
Focus on Personalized Medicine
Munich benefits in particular from close interaction between academic research and the biotech industry. The region is characterized by a strong focus on “personalized pharmaceutical biotechnology”. Munich’s profile in this area was further sharpened by a national funded program “m4- Personalized Medicine and Targeted Therapies” in the range of 100m €, which was coordinated by the local cluster management organisation BioM from 2010 to 2015. In this particular program the infrastructural measures for combining biomarker research and validation with drug development and diagnostics could be optimized and a new central approach to Munich Biobanking and Clinical Trial Services now improves the interaction of industry and academic institutes even further – for the sake of the patient.
Further information can be obtained: